Intellia's CRISPR Dream Just Hit a Wall

And this wasn't the first warning sign. Earlier in 2025, another patient in the TTR program had experienced a separate grade 4 liver event. Two serious liver toxicity cases in the same program is a pattern regulators can't ignore, even if the overall incidence stayed below 1% of the more than 450 patients dosed.

The Fix (and What It Cost)

The FDA lifted the clinical hold on MAGNITUDE-2 in January 2026, and the hold on MAGNITUDE in March 2026, but with strings attached. Think of it like getting your driver's license back after a DUI: you can drive again, but there are conditions.

The new requirements include more frequent liver monitoring after dosing, guidance for short-term steroid treatment if liver enzymes start climbing, and stricter exclusion criteria to keep higher-risk patients out of the trials. For MAGNITUDE specifically, patients with a left ventricular ejection fraction below 25% (meaning their hearts are already severely weakened) are now excluded, along with anyone with recent cardiovascular instability.

These guardrails are sensible. But they also slow enrollment, shrink the eligible patient pool, and raise an uncomfortable question: if this therapy needs this many safety precautions, how practical will it be in the real world?

Wall Street's Verdict: Ouch

The stock told the story before the analysts did. Shares dropped roughly 17% in after-hours trading when the liver toxicity was first disclosed. And the analyst community has been steadily dialing back expectations ever since.

Wells Fargo slashed its price target from $45 to $17 and downgraded the stock. Bernstein moved to a Market Perform rating with a $14.50 target, citing platform safety risk. RBC Capital cut its target from $21 to $14. The average analyst price target now sits around $20, a far cry from the days when some firms had targets north of $95.

Not everyone is bearish. Cantor Fitzgerald kept an Overweight rating with a $65 target, calling the sell-off an overreaction. H.C. Wainwright maintained its Buy rating and actually raised its target to $30. The bulls argue the liver signal appears isolated to the TTR program and doesn't contaminate Intellia's broader platform.

CEO John Leonard has echoed that view, stating he believes the problem is limited to Intellia's TTR program, not the lipid nanoparticle delivery system that carries CRISPR into liver cells. His reasoning: the liver event occurred weeks after infusion, not immediately, suggesting the issue relates to the specific gene target rather than the delivery vehicle.

The Bigger Picture for CRISPR

Intellia isn't operating in a vacuum. This safety scare lands at a pivotal moment for in vivo gene editing, where therapies are injected directly into patients rather than editing cells in a lab dish.

The field has already seen a fatal case in a Duchenne muscular dystrophy trial using AAV-delivered CRISPR, where a patient died from acute respiratory distress syndrome six days after infusion. Graphite Bio halted its sickle cell CRISPR trial after patients developed dangerously low blood counts. And researchers keep discovering that CRISPR-induced DNA breaks can cause large deletions, chromosomal rearrangements, and other genomic chaos that might not show up for years.

Intellia's liver safety signal adds another data point to a growing file. It doesn't doom in vivo CRISPR, but it does reinforce a hard truth: rewriting human DNA inside a living body is extraordinarily difficult, and the margin for error is razor-thin.

What's Still Working (and What to Watch)

Here's the silver lining: Intellia's other major program, lonvoguran ziclumeran (NTLA-2002) for hereditary angioedema, was never paused and continues advancing. The company completed its Phase 2 study with positive results, selected a 50 mg dose for pivotal development, and has started a rolling BLA submission targeting a potential approval and launch in early 2027.

Meanwhile, competitors are circling. CRISPR Therapeutics already has an approved ex vivo product (Casgevy) and is pushing its own in vivo cardiovascular programs into the clinic. Verve Therapeutics and Beam Therapeutics are advancing base-editing approaches that avoid the double-strand DNA breaks central to Intellia's method, which could prove safer in the long run.

For Intellia, the next few months are critical. MAGNITUDE and MAGNITUDE-2 need to re-enroll smoothly under the new safety protocols. The HAE program needs to deliver strong Phase 3 data and a clean BLA submission. And the company needs to convince regulators, physicians, and patients that one bad liver event doesn't define the platform.

The promise of a single injection that cures genetic disease is still alive. But it just got a lot harder to deliver.